Zach Hartman | Authors





Denosumab Most Effective in High-Risk Prostate Cancer Patients

October 02, 2013

The anti-RANKL antibody denosumab is more effective for preventing bone metastasis in men with high-risk castration-resistant prostate cancer compared with low-risk disease, according to results of a new study.

FDG-PET May Help Predict Lung Cancer Survival

September 23, 2013

Analysis of 18F FDG-PET standardized uptake values may be a useful technique for predicting survival in patients with inoperable stage III non–small-cell lung carcinoma, according to a new study.

Night Shifts Implicated in Increased Prostate Cancer Risk

September 05, 2013

Shift work is positively associated with higher levels of prostate-specific antigen (PSA) levels in men between the ages of 40 and 65, according to results of a new study.

Improved Survival in Foreign-Born Hispanics With Lung Cancer

August 27, 2013

Among non–small-cell lung carcinoma (NSCLC) patients, foreign-born Hispanics show less cancer-related mortality compared with US-born Hispanics and non-Hispanic whites, in part due to social and cultural environment, according to results of a new study.

Crizotinib Ups PFS in ALK-Positive NSCLC

July 25, 2013

The ALK-inhibitor crizotinib leads to longer progression-free survival than chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer (NSCLC), according to results of a phase III clinical trial.

Gene Expression Test Shows Promise for Lung Cancer Diagnosis

July 25, 2013

An assay system for gene expression analysis of paraffin-embedded patient samples is predictive of lung cancer histologic type, according to results published in the Journal of Molecular Diagnostics.

BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer

June 20, 2013

The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine leads to a significant improvement in progression-free survival compared with placebo in advanced and metastatic HER2-positive breast cancer.

ASCO: Post-Surgery Surveillance Found Safe in Seminoma

June 17, 2013

Surveillance of patients with stage I seminoma following orchiectomy can spare a majority of patients from adjuvant chemotherapy with a low risk of relapse, according to results presented at the 2013 ASCO meeting.